Lyell Immunopharma, Inc. (LYEL)
22.53
+0.48
(+2.18%)
USD |
NASDAQ |
Mar 06, 10:31
Lyell Immunopharma Cash from Investing (TTM) : 138.97M for Sept. 30, 2025
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| Insmed, Inc. | -64.58M |
| Nektar Therapeutics | 58.64M |
| GT Biopharma, Inc. | 0.00 |
| Regeneron Pharmaceuticals, Inc. | -629.10M |
| Vertex Pharmaceuticals, Inc. | -945.40M |